7th Sep 2016 15:02
Vectura Group plc
Results of the Annual General Meeting held on 7 September 2016 at the offices of Covington & Burling LLP, 265 Strand, London WC2R 1BH.
Chippenham, UK, 7 September 2016: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed on a poll, the results of which are set out below:
| Resolution | Votes for | % of votes cast | Votes against | % of votes cast | Votes withheld* |
1 | To receive the Annual Report & Accounts to 31 March 2016 | 551,934,169 | 97.78 | 12,512,658 | 2.22 | 373,172 |
2 | To approve the Directors' Remuneration Report | 537,667,257 | 95.24 | 26,853,225 | 4.76 | 299,517 |
3 | To elect James Ward-Lilley | 559,939,018 | 99.19 | 4,564,596 | 0.81 | 316,385 |
4 | To elect Frank Condella | 403,554,380 | 74.08 | 141,183,513 | 25.92 | 20,082,106 |
5 | To elect Andrew Derodra | 554,739,795 | 98.27 | 9,764,639 | 1.73 | 315,565 |
6 | To elect Dr Thomas Werner | 553,561,225 | 98.87 | 6,343,596 | 1.13 | 4,915,051 |
7 | To re-elect Bruno Angelici | 529,239,785 | 97.10 | 15,792,009 | 2.90 | 19,788,205 |
8 | To re-elect Dr T Phillips | 559,960,406 | 99.20 | 4,541,963 | 0.80 | 317,630 |
9 | To re-elect Dr Susan Foden | 552,754,573 | 98.73 | 7,133,740 | 1.27 | 4,931,686 |
10 | To re-elect Neil Warner | 558,720,725 | 99.79 | 1,166,583 | 0.21 | 4,932,691 |
11 | To re-elect Dr P Andersson | 561,935,088 | 99.55 | 2,566,283 | 0.45 | 318,453 |
12 | To re-appoint Deloitte LLP as Auditor | 548,806,722 | 98.17 | 10,255,786 | 1.83 | 5,757,491 |
13 | To authorise the Directors to determine the remuneration of the Auditor | 539,539,681 | 96.51 | 19,538,961 | 3.49 | 5,741,357 |
14 | To authorise the Directors to amend rules of the Vectura Group PLC Share Incentive Plan and establish similar plans overseas | 557,266,537 | 98.68 | 7,447,299 | 1.32 | 104,300 |
15 | To grant the Directors authority to allot shares | 546,290,810 | 96.74 | 18,431,862 | 3.26 | 91,611 |
16 | To grant the Directors authority to disapply pre-emption rights | 558,267,446 | 98.84 | 6,531,790 | 1.16 | 20,736 |
17 | To grant the Directors authority to disapply pre-emption rights in respect of additional shares allotted for an acquisition or capital investment | 521,881,705 | 92.41 | 42,844,305 | 7.59 | 93,989 |
18 | To authorise the calling of General Meetings on 14 days' notice | 550,234,593 | 97.47 | 14,292,724 | 2.53 | 292,681 |
*NB: The percentage of votes cast for and against excludes withheld votes.
Enquiries:
Vectura Group plc | +44 (0)1249 667700 |
|
|
John Murphy Company Secretary |
|
One Prospect West Chippenham Wiltshire SN14 6FH
|
|
Citigate Dewe Rogerson | +44 (0)20 7638 9571 |
David Dible / Mark Swallow |
|
Notes for Editors:
About Vectura
Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases. In June 2016 Vectura completed a merger with Skyepharma PLC.
Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.
For further information, please visit Vectura's website at www.vectura.com.
Related Shares:
VEC.L